No Stock Yet
FibroGen (NASDAQ:FGEN) Shares Gap Up to $12.44
Shares of FibroGen, Inc. (NASDAQ:FGEN – Get Rating) gapped up prior to trading on Wednesday . The stock had previously closed at $12.44, but opened at $13.05. FibroGen shares last traded at $12.86, w
SHLS, FORM, HOWL and VWE Are Among After Hour Movers
Gainers: Shoals Technologies Group (SHLS) +6.2%. FormFactor (FORM) +5.0%. eXp World Holdings (EXPI) +5.0%. Vodafone Group (VOD) +4.8%. Embark Technology (EMBK) +4.2%. Losers: Werewolf Therapeutics (
FibroGen, Inc.'s (NASDAQ:FGEN) Stock Has Plunged to US$12.87, but Insiders May Have Sold Too Soon at an Even Lower Price of US$11.58
Even though FibroGen, Inc. (NASDAQ:FGEN) has fallen by 5.9% over the past week , insiders who sold US$152k worth of stock over the past year have had less luck. Insiders would probably have been bett
Short Volatility Alert: FibroGen, Inc.
On Tuesday, shares of FibroGen, Inc. (NASDAQ:FGEN) experienced volatile short activity. After the activity, the stock price went down -4.38% to $12.87. The overall sentiment for FGEN has been Bearish.
FibroGen Concludes Dosing In Late-Stage Blood Cell Disorder Study, Sees Top-line Data In H1 2023
FibroGen, Inc. (NASDAQ:FGEN) has completed patient enrollment for MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with lower risk transfusion-dependent myelodysp
FibroGen Announces Completion of Patient Enrollment in MATTERHORN
FibroGen announced completion of patient enrollment for MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with lower risk transfusion-dependent myelodysplastic syn
FibroGen Completes Patient Enrollment for Phase 3 Study of Anemia Drug Candidate
07:11 AM EDT, 08/26/2022 (MT Newswires) -- FibroGen (FGEN) said Friday it has completed its patient enrollment for the phase 3 study of roxadustat, which is intended for anemia in patients with lower-
FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients With Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)
- 141 MDS Patients Enrolled -- Topline Data Anticipated 1H:2023 - SAN FRANCISCO, Aug. 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced completion of patient enrollment for MATTERHORN, a Phase 3 clinical study of roxadustat
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Provides Update of Its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), provides an update to KSF's continued investigation into FibroGen, Inc. (NASDAQ:FGEN). On April 6, 2021, the Company disclo
FibroGen Management to Meet Virtually With William Blair
Virtual Meeting to be held on August 26 hosted by William Blair.
No Stock Yet